1 / 12

Doh Lee, M.D., Ph.D., Jin Hyoung Kim, M.D., Suk Kyue Choi, M.D., Se Hoon Park, M.D.

The Effect of Bevacizumab and Ranibizumab Injection on Corneal Neovascularization. Doh Lee, M.D., Ph.D., Jin Hyoung Kim, M.D., Suk Kyue Choi, M.D., Se Hoon Park, M.D. Department of Ophthalmology, Ilsan Paik Hospital, Inje University College of Medicine, Gyeonggi, Korea

ganya
Download Presentation

Doh Lee, M.D., Ph.D., Jin Hyoung Kim, M.D., Suk Kyue Choi, M.D., Se Hoon Park, M.D.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Effect of BevacizumabandRanibizumab Injection on Corneal Neovascularization Doh Lee, M.D., Ph.D., Jin Hyoung Kim, M.D., Suk Kyue Choi, M.D., Se Hoon Park, M.D. Department of Ophthalmology, Ilsan Paik Hospital, Inje University College of Medicine, Gyeonggi, Korea Authors have no financial interest

  2. PURPOSE • To evaluate the effect of regression and treatment of subconjunctival and intralesional Bevacizumab (AvastinⓇ) and Ranibizumab (LucentisⓇ) injection on corneal neovascularization (CNV) resulting from different ocular surface disorders

  3. METHODS • Group I - Bevacizumab (AvastinⓇ; Genentech, Inc., San Francisco, CA) - 1.25 mg/0.05cc injection only (n=5) under topical anesthesia • Group II - Ranibizumab (LucentisⓇ ; Genentech, Inc., San Francisco, CA) - 0.5 mg/0.05cc injection only (n=5) under topical anesthesia

  4. METHODS • Charateristics of patients • Patients were followed up at 1, 7, 30 days after treatment. • Used Image J software (Wayne Rasband at the Research Services Branch, National Institute of Mental Health, Bethesda, MD) to analyze the vascularized corneal area.

  5. Results - Area of CNV Bevacizumab 1.25mg/0.05cc injection (Group I) < Post herpetic CNV with corneal opacity > Pre injection Post injection (POD # 7) < Post KP CNV d/t Chemical burn > Pre injection Post injection (POD # 7)

  6. Results - Area of CNV Bevacizumab 1.25mg/0.05cc injection (Group I) < CNV d/t Lipid degeneration > < CNV d/t corneal ulcer > < Post Pterygium OP. > Pre injection Pre injection Pre injection Post injection (POD # 7) Post injection (POD # 7) Post injection (POD # 7)

  7. Results - Area of CNV Bevacizumab 1.25mg/0.05cc injection (Group I) (By using Image J software)

  8. Results - Area of CNV Ranibizumab 0.5mg/0.05cc injection(Group II) < Post KP CNV > Pre injection Post injection (POD # 7) < CNV with corneal opacity d/t Lipid keratopathy > Pre injection Post injection (POD # 7)

  9. Results - Area of CNV Ranibizumab 0.5mg/0.05cc injection (Group II) < Post herpetic CNV with corneal opacity > Pre injection Post injection (POD # 7) < Post herpetic CNV with corneal opacity > Pre injection Post injection (POD # 7)

  10. Results - Area of CNV Ranibizumab 0.5mg/0.05cc injection (Group II) (By using Image J software)

  11. Conclusions & Discussions • Subconjunctival and intralesional Bevacizumab injection effectively regress CNV induced by various causes, whereas there is no significant effect for CNS after Ranibizumab injection. • Bevacizumab injection were seems to be more effective to reduce CNV • than Ranibizumab injection. • Bevacizumab injection showed significant regression of CNV in short • period of time. After one month Bevacizumab injection, CNV had • tendency to recur and re-growth.

  12. Conclusions & Discussions • Subconjunctival and intralesional Bevacizumab injection could be considered a treatment option for the CNVs. • Further research is needed to assess the potential duration, side – effects and minimal effective dose.

More Related